Pfizer on Tuesday reported fourth-quarter results that topped estimates even amid dwindling demand for its Covid products, while reaffirming its modest 2026 guidance that rattled investors in December.
The pharmaceutical giant is looking to longer-term investments in its pipeline, including its $10 billion acquisition of the obesity biotech Metsera, to counter waning Covid product sales and declines from older drugs. Pfizer moved to show the promise of that investment Tuesday, when it also reported mid-stage data showing that an obesity injection from Metsera can be taken once a month and drive solid weight loss.
In addition, Pfizer is on track to cut costs by about $7.7 billion by the end of 2027 as part of two separate initiatives.
Here’s what the company reported for the fourth quarter compared with what Wall Street was expecting, based on a survey of analysts by LSEG:
Advertisement
Earnings per share: 66 cents adjusted vs. 57 cents expected
Revenue: $17.56 billion vs. $16.95 billion expected
Pfizer reported revenue of $17.56 billion for the fourth quarter, down around 1% from the same period a year ago. That is largely because of lower demand for its Covid vaccine and Paxlovid, an antiviral pill for the virus.
The company booked a net loss of $1.65 billion, or 29 cents per share. That compares with net income of $410 million, or 7 cents per share, during the same period a year ago.
Excluding certain items, including restructuring charges and costs associated with intangible assets, the company posted earnings per share of 66 cents for the quarter.
Pfizer expects 2026 adjusted profit to come in between $2.80 and $3 per share, and revenue to total $59.5 billion to $62.5 billion. Those sales would largely be flat compared with 2025 revenue.
Pfizer previously said the lackluster revenue outlook comes in part from declining sales of its Covid vaccine and antiviral pill Paxlovid, which it expects to fall by about $1.5 billion year over year to $5 billion.
Advertisement
The company also pointed to another roughly $1.5 billion year-over-year expected drop in sales due to certain products losing their market exclusivity. Some blockbuster drugs, such as the company’s pneumonia vaccine Prevnar, are facing more competition from rivals.
More CNBC health coverage
In December, Pfizer CFO Dave Denton told investors there is also “price compression and margin compression baked into” the company’s 2026 guidance as it plans to provide “deeper discounts” in its Medicaid business as part of a landmark drug pricing deal struck with President Donald Trump.
Under that agreement, Pfizer agreed to sell its existing drugs to Medicaid patients at the lowest price offered in other developed countries and guarantee the same “most-favored-nation” pricing on its new drugs for Medicare, Medicaid and commercial payers. In return, the company will get a three-year exemption from tariffs.
Pfizer’s Xeljanz and Xeljanz XR, treatments for rheumatoid arthritis and other inflammatory conditions, were selected in January for the third round of Medicare drug price negotiations. New negotiated prices will come into effect in 2028.
A long-term investor focused on quality growth stocks at a reasonable price. My investment objective is to identify market asymmetries with positive reward-to-risk. I invest in high-quality, wide-moat companies that generate strong cash flow and trade at a fair price relative to their value. Please feel free to subscribe to my channel to support its development.
Analyst’s Disclosure: I/we have a beneficial long position in the shares of TSM either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
I am a full-time analyst interested in a wide range of stocks. With my unique insights and knowledge, I hope to provide other investors with a contrasting view of my portfolio, given my particular background.If you have any questions, feel free to reach out to me via a direct message on Seeking Alpha or leave a comment on one of my articles.
Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
The analysis is provided exclusively for informational purposes and should not be considered professional investment advice. Before investing, please conduct personal in-depth research and utmost due diligence, as there are many risks associated with the trade, including capital loss.
Advertisement
Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
INDIO, California — Rihanna is not performing at the Coachella Valley Music and Arts Festival in 2026, dashing hopes among fans who had speculated she might make a rare live appearance or even headline after years away from the stage.
Rihanna
The 2026 lineup, announced in September 2025, features headliners Sabrina Carpenter on Fridays, Justin Bieber on Saturdays and Karol G on Sundays — the first Latina artist to top the bill. Other major acts include The Strokes, Addison Rae, Young Thug, FKA twigs and Anyma’s immersive ÆDEN project. Rihanna’s name appears nowhere on the official poster or daily schedules released by promoter Goldenvoice.
As the festival wraps its second weekend on April 19, Rihanna was instead spotted as a high-profile attendee. She cheered on boyfriend A$AP Rocky during his surprise appearance at Doja Cat’s set on the first weekend, creating viral moments that dominated social media. Fans posted videos of the Barbadian superstar in the crowd, looking stylish in festival attire and supporting her partner without stepping onto any stage herself.
Rihanna, 38, has not toured since the Anti World Tour wrapped in 2016 and has limited her live performances in recent years, focusing instead on her Fenty Beauty and Savage X Fenty empires, acting roles and family life with A$AP Rocky and their children. Her last major stage moment was the 2023 Super Bowl halftime show, which drew record viewership but also highlighted the challenges of large-scale performances after a long hiatus.
Industry observers and past reporting indicate Rihanna passed on headlining opportunities in recent Coachella cycles, including 2025 discussions where both she and Kendrick Lamar reportedly declined slots. Sources cited her lack of need for the exposure or financial incentive, alongside commitments to business ventures and motherhood. Bloomberg and other outlets noted similar decisions in prior years, with Rihanna prioritizing selective, high-impact appearances over festival bookings that require extensive rehearsal and two-weekend commitments.
Advertisement
Coachella’s demanding outdoor desert environment, shared production resources and variable weather add logistical hurdles for artists who prefer controlled arena or stadium settings. Rihanna’s performances are known for their high-energy hits, elaborate visuals and fashion statements — elements that shine brightest in dedicated tours. Rumors of a 2026 world tour or UK stadium comeback to mark the 10th anniversary of Anti have circulated, but no confirmed dates overlap with Coachella weekends.
Fans expressed disappointment when the lineup dropped without her, sparking Threads posts pleading “RIHANNA, HEADLINE COACHELLA YOU COWARD!!” and betting odds that listed her as a long-shot for surprise cameos at 20/1. As the festival progressed without a Rihanna set, attention shifted to actual surprises: Becky G joining Karol G, Lizzo and other guests popping up across stages. No Rihanna performance materialized, even as speculation lingered into the second weekend.
Her presence in the crowd still generated buzz. Videos showed Rihanna vibing to sets, with one caption noting she was “just watching and still making history.” The moment echoed past Coachella appearances where her star power amplified the event without her needing a microphone. Supporters praised her low-key attendance as proof she remains a cultural force, while others hoped for a last-minute guest spot that never came.
Rihanna’s selective approach to live shows aligns with her career evolution. Since releasing Anti in 2016, she has released only occasional singles and focused on non-music projects that have made her one of the world’s wealthiest entertainers. Fenty Beauty alone revolutionized the industry with inclusive shade ranges, while Savage X Fenty brought innovative fashion to lingerie. These ventures, combined with family priorities, have reduced her appetite for the rigorous demands of touring or festival circuits.
Advertisement
Music analysts suggest Coachella benefits from artists in active album cycles who can leverage the platform for promotion. Rihanna, with no new full-length project driving momentum, may view the desert slot as less essential. Goldenvoice has successfully built sellout crowds around rising stars like Sabrina Carpenter and established names like Bieber and Karol G, proving the festival can thrive without perennial superstars every year.
For Little Monsters and Rihanna’s Navy, the annual Coachella speculation has become routine. Many hoped 2026 might mark her return after the Super Bowl buzz, especially with rumors of new music. Instead, her attendance alongside A$AP Rocky reinforced her status as a style and celebrity icon who can command attention simply by showing up. Photos of the couple enjoying noodles, dancing and supporting friends circulated widely, adding glamour to the VIP sections.
Coachella 2026 has delivered memorable moments without her. Sabrina Carpenter brought celebrity cameos and polished pop anthems. Justin Bieber delivered a nostalgic, YouTube-inspired set that divided opinions but drew huge crowds. Karol G made history with vibrant Latin hits and guest spots, celebrating cultural representation. Anyma’s ÆDEN project offered immersive visuals despite weather adjustments. These performances kept social feeds active and livestreams popular on YouTube.
The festival’s appeal lies in discovery, fashion and unexpected collaborations rather than relying on any single megastar. Yet Rihanna’s absence fuels ongoing conversations about what it would take to bring her back. Past guest appearances, such as joining Calvin Harris years ago, showed her impact, but a full set would require significant preparation she appears unwilling to commit at this stage.
Advertisement
As of April 18, 2026, no official statements from Rihanna’s team or Goldenvoice address her non-performance. Representatives for both have not responded to inquiries. In the meantime, fans dissect her Instagram stories and crowd sightings for clues about future plans, including potential tour announcements later in 2026.
Rihanna’s career trajectory shows strategic pacing. After dominating the 2000s and 2010s with hits like “Umbrella,” “Diamonds” and “Work,” she transitioned into a multifaceted mogul. Her rare live outings become events precisely because of their scarcity. Coachella, while prestigious, competes with stadium tours, residencies or brand-driven spectacles that better suit her current priorities.
Online discussions reflect divided opinions. Some argue she has “outgrown” traditional festivals and should focus on her own productions. Others believe a Coachella headline could revitalize her performing career and introduce new music to a massive audience. Betting markets and rumor mills kept her name alive, but reality aligned with the official lineup.
The broader music industry notes that superstars like Rihanna, Taylor Swift and others often skip Coachella in favor of autonomous tours where they control every detail. Festival economics and scheduling conflicts play roles, especially for artists balancing multiple businesses and family.
Advertisement
As Coachella 2026 concludes, the desert sands will host another successful edition centered on its announced roster and organic surprises. Rihanna’s non-performance does not diminish the event’s cultural weight but highlights her enduring mystique — she can dominate headlines simply by attending.
Fans hoping for a Rihanna Coachella set may need to wait for 2027 or beyond, or catch her if she launches the rumored 2026 tour dates. For now, her crowd appearance alongside A$AP Rocky provided enough star power to keep conversations going long after the final set ends.
Whether she returns to the main stage in the future remains one of music’s tantalizing questions. Until then, Rihanna continues to prove that sometimes the biggest presence at Coachella is the one not performing at all.
TUCSON, Arizona — More than 75 days after her abduction from her Catalina Foothills home, concerns about Nancy Guthrie’s health have intensified, with medical experts warning that the 84-year-old’s survival without her critical heart medications remains highly uncertain and increasingly unlikely as time passes.
Nancy Guthrie, the mother of NBC’s “Today” co-anchor Savannah Guthrie, was last seen on the evening of Jan. 31, 2026, when a family member dropped her off at her residence. She failed to appear for a planned church service the next morning. Evidence at the scene — including blood believed to be hers on the porch, signs of a struggle, and doorbell camera footage of a masked intruder with a handgun — led authorities to classify the case as a targeted abduction rather than a voluntary disappearance.
Pima County Sheriff Chris Nanos and the FBI have confirmed that Guthrie left her home without her essential daily medications, including those for her pacemaker, high blood pressure and cardiac issues. Medical professionals have repeatedly described this as a life-threatening situation. Cardiologists and sleep experts have highlighted the elevated risk of heart attack, stroke or other complications, especially if she was abruptly awakened around 2 a.m. during the abduction, potentially triggering sleep inertia and added cardiac stress.
Dr. Ankur Kalra, a cardiologist, noted that Guthrie’s pacemaker indicates underlying heart rhythm problems, and missing blood thinners or blood pressure medications could quickly lead to dangerous clots or hypertensive crises. Sleep specialist Pat Byrne warned that the combination of sudden awakening, confusion and her pre-existing conditions placed her at “very high risk” of a cardiac event in the immediate hours after the abduction. As weeks turned into months without any confirmed contact or proof of life, those risks have only compounded.
Advertisement
Savannah Guthrie has spoken publicly about her mother’s health vulnerabilities in emotional interviews. In her first return to the “Today” show in early April, she described the family’s anguish and pleaded for anyone with information to come forward. She has expressed hope that her mother is still alive but acknowledged the growing uncertainty surrounding her medical needs.
As of April 18, 2026 — approximately Day 77 of the search — Nancy Guthrie remains missing. The FBI continues analyzing DNA evidence recovered from the home, including a hair sample and gloves with unknown male DNA, but officials clarified this week that no major new breakthroughs have emerged. The Pima County Sheriff’s Department stated that DNA testing is ongoing between a private Florida lab and the FBI, with results still pending.
Ransom notes demanding millions, some referencing Bitcoin, were received shortly after the disappearance. The family responded publicly, offering to communicate if proof of life was provided, but no verified follow-up from the abductor has been confirmed. Investigators treat the case as an active kidnapping with possible financial motives tied to Savannah Guthrie’s high-profile status.
The prolonged absence without medication has become a central focus for medical experts consulted by media outlets. A pacemaker patient missing doses risks arrhythmia, while uncontrolled high blood pressure can lead to organ damage or stroke. At 84, with reported limited mobility and chronic conditions, Guthrie’s window for safe recovery narrows daily. Some physicians have described the situation as potentially “fatal” without intervention, though no official determination of her condition has been made since she vanished.
Advertisement
Search efforts have included extensive neighborhood canvassing, review of surveillance footage, and coordination with federal agencies. Cadaver dogs were deployed earlier but later placed on hold. Patrols in the Catalina Foothills area have increased, and authorities continue urging residents to check home security cameras from late January and early February for any suspicious activity.
The family has offered a substantial reward — reportedly up to $1 million — for information leading to Nancy Guthrie’s safe return. Additional rewards from the FBI and local crime stoppers bring the total incentive higher. Savannah Guthrie has used her platform to appeal directly to the public, emphasizing that even small details could help.
No arrests have been made, and no suspect has been publicly identified. Sheriff Nanos has cleared all immediate family members of involvement, describing them as cooperative victims. The investigation has examined possible links to the family’s visibility but treats the abduction as targeted rather than random.
Public speculation has surged online, with some unverified claims of breakthroughs quickly debunked by authorities. The sheriff’s department recently addressed false social media posts about DNA results, stressing that testing remains ongoing and no resolution has been reached.
Advertisement
For the Guthrie family, the uncertainty is compounded by health fears. Savannah has described sleepless nights worrying about her mother’s well-being, medication access and emotional state. Friends and church community members have held vigils, praying for her safe return while acknowledging the medical realities.
As the case enters its third month, experts in abduction investigations note that time is critical for elderly victims with medical dependencies. Without access to prescription drugs, survival odds diminish rapidly. While some abductors have provided medication in past ransom cases, no such arrangement has been confirmed here.
The FBI maintains a dedicated tip line and online portal for information. Anyone with knowledge of the abduction, sightings of Guthrie, or details about suspicious vehicles or individuals in the area is urged to contact authorities immediately. Tips can remain anonymous.
Nancy Guthrie’s story has drawn national attention due to her daughter’s prominence, shining a light on vulnerabilities faced by elderly individuals and the challenges of high-profile abductions. It has also renewed discussions about home security, medication access during crises and the emotional toll on families.
Advertisement
As of Saturday, April 18, 2026, hope persists that Nancy Guthrie will be found alive and that her health can be stabilized upon recovery. Medical professionals stress that even after prolonged absence, prompt medical care could mitigate damage if she is located soon.
The investigation continues with full resources from local, state and federal agencies. Savannah Guthrie has returned to her anchoring duties while remaining actively involved behind the scenes, balancing public appeals with private family support.
For now, the question of Nancy Guthrie’s health hangs heavily over the case. Without her medications and with no confirmed updates on her condition, experts remain deeply concerned. The family and authorities continue to plead for public assistance, emphasizing that one piece of information could bring her home and allow her to receive the urgent care she needs.
Anyone with information is encouraged to call the FBI at 1-800-CALL-FBI or submit tips online. The search for Nancy Guthrie — and answers about her health — remains active and urgent.
Wolf Report is a senior analyst and private portfolio manager with over 10 years of generating value ideas in European and North American markets.He covers the markets of Scandinavia, Germany, France, UK, Italy, Spain, Portugal and Eastern Europe in search of reasonably valued stock ideas.
Analyst’s Disclosure: I/we have a beneficial long position in the shares of NGG either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
While this article may sound like financial advice, please observe that the author is not a CFA or in any way licensed to give financial advice. It may be structured as such, but it is not financial advice. Investors are required and expected to do their own due diligence and research prior to any investment.
Advertisement
Short-term trading, options trading/investment and futures trading are potentially extremely risky investment styles. They generally are not appropriate for someone with limited capital, limited investment experience, or a lack of understanding for the necessary risk tolerance involved.
I own the European/Scandinavian tickers (not the ADRs) of all European/Scandinavian companies listed in my articles. I own the Canadian tickers of all Canadian stocks I write about.
Please note that investing in European/Non-US stocks comes with withholding tax risks specific to the company’s domicile as well as your personal situation. Investors should always consult a tax professional as to the overall impact of dividend withholding taxes and ways to mitigate these.
Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
HDFC Bank Limited (HDB) Q4 2026 Earnings Call April 18, 2026 6:30 AM EDT
Company Participants
Srinivasan Vaidyanathan – Chief Financial Officer Sashidhar Jagdishan – MD, CEO & Director Kaizad Bharucha – Deputy MD & Director
Conference Call Participants
Advertisement
Mahrukh Adajania Nitin Aggarwal – Motilal Oswal Securities Limited, Research Division Kunal Shah – Citigroup Inc., Research Division Pranav Gundlapalle – Bernstein Institutional Services LLC, Research Division Seshadri Sen – Emkay Global Financial Services Ltd., Research Division Rikin Shah – IIFL Research Abhishek Murarka – HSBC Global Investment Research Piran Engineer – CLSA Limited, Research Division
Presentation
Operator
Advertisement
Ladies and gentlemen, good day, and welcome to HDFC Bank Limited Q4 and Full Year FY 2026 Earnings Conference Call on the financial results presented by the management of HDFC Bank. [Operator Instructions] Please note that this conference is being recorded.
I now hand the conference over to Mr. Srinivasan Vaidyanathan, Chief Financial Officer, HDFC Bank. Thank you, and over to you, Mr. Vaidyanathan.
Srinivasan Vaidyanathan Chief Financial Officer
Advertisement
Thank you. Thank you, Nirav. Good evening, and warm welcome to all the participants. Today, we have with us our Chairman, Mr. Keki Mistry; our CEO, Mr. Sashi Jagdishan; and our Deputy Managing Director, Mr. Kaizad Bharucha.
I will hand off for opening remarks to Sashi. Over to you, Sashi, then we can get on to the other agenda.
Sashidhar Jagdishan MD, CEO & Director
Advertisement
Thank you, Srini, and thank you all. Good afternoon to you, and welcome to the full year FY ’26 annual results call. Let me dive straight into the key aspects of FY ’26 performance. We had estimated the system credit growth to be around 10.5% to 11.5%. We did 12%, up from 5.5% last year. As you can see, there is positive momentum as we had expected. Deposit growth rate at 14.4% continues to grow faster than the credit growth, which is what we’ve always been doing. The growth rate is better than the
You must be logged in to post a comment Login